Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome clinical trials
1 of 2 indexed BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome: 2 US clinical trials tracked, 1 recruiting.
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is OHSU Knight Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition brca12-associated-hereditary-breast-and-ovarian-cancer-syndrome
OPEN 1 | RECR 50% | LATE 0 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Identifying and Caring for Individuals With Inherited Cancer Syndrome
OHSU Knight Cancer Institute
NCT04494945
Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study
Ohio State University Comprehensive Cancer Center
NCT06534424
Phase Distribution
Phase data not available
Top Sponsors
Named interventions
Most-linked intervention names on BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- OHSU Knight Cancer Institute sponsors the most BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome trials on record, review their full trial history before evaluating a specific study. See OHSU Knight Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome condition card totals 2 registered trials; most-linked intervention Biospecimen Collection; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.